CAMP4 THERAPEUTICS CORPORATION (CAMP) financial statements
CAMP4 THERAPEUTICS CORPORATION reported revenue of $3M in fiscal 2025, up 216.1% a year over 2 years.
Net income was -$80M and the operating margin -1502.4%, against -14822.6% in 2023.
Free cash flow was -$30M.
The diluted share count rose 7592% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from CAMP4 THERAPEUTICS CORPORATION's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $350,000 | $652,000 | $3M |
| Research and development | $41M | $39M | $38M |
| Selling, general and admin | $12M | $15M | $17M |
| Operating income | -$52M | -$53M | -$53M |
| Income tax | $0 | $0 | $0 |
| Net income | -$49M | -$52M | -$80M |
| EPS (diluted) | -$124.80 | -$11.04 | -$2.65 |
| Diluted shares | 0M | 5M | 30M |
| Operating margin | -14822.6% | -8142.3% | -1502.4% |
| Net margin | -14083.1% | -7943.4% | -2298.5% |
Balance sheet
Fiscal years, from CAMP4 THERAPEUTICS CORPORATION's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cash and short-term investments | $38M | $64M | $110M |
| Total current assets | $40M | $66M | $114M |
| Property, plant and equipment | $5M | $4M | $2M |
| Total assets | $55M | $78M | $118M |
| Total current liabilities | $8M | $10M | $16M |
| Total liabilities | $17M | $15M | $70M |
| Shareholders' equity | -$124M | $63M | $48M |
| Net debt | -$38M | -$64M | -$110M |
Cash flow
Fiscal years, from CAMP4 THERAPEUTICS CORPORATION's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | -$44M | -$46M | -$30M |
| Capital spending | $678,000 | $441,000 | $279,000 |
| Free cash flow | -$45M | -$46M | -$30M |
| Stock-based compensation | $3M | $4M | $4M |
| Free cash flow margin | -12809.4% | -7055.7% | -852.8% |
Questions
What was CAMP4 THERAPEUTICS CORPORATION's revenue in 2025?
$3M in fiscal 2025, from its 10-K filing.
How much free cash flow does CAMP4 THERAPEUTICS CORPORATION generate?
-$30M in fiscal 2025 (operating cash flow minus capital spending).
From CAMP4 THERAPEUTICS CORPORATION's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.